Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Kobayashi H, Harabuchi Y.
Kono M, et al. Among authors: takahara m.
Cancer Immunol Immunother. 2021 Dec;70(12):3421-3434. doi: 10.1007/s00262-021-02940-5. Epub 2021 Apr 18.
Cancer Immunol Immunother. 2021.
PMID: 33866408
Free PMC article.